While the phrase "about a 70% five-year survival rate" is often cited for Ewing sarcoma, the reality of a patient's prognosis is far more nuanced and depends dramatically on a single, critical factor: the stage of the cancer at diagnosis.
Key Takeaways
- The 5-year overall survival (OS) rate for all Ewing sarcoma patients diagnosed between 1973-2013 per SEER database is approximately 62%
- In a cohort of 1,957 patients, the 5-year OS for localized disease was 73%, dropping to 36% for metastatic
- SEER 18 data from 2004-2015 shows 5-year OS of 70.4% for non-metastatic Ewing sarcoma
- For localized Ewing sarcoma (stage I/II), 5-year event-free survival (EFS) is 65-75%
- Metastatic Ewing sarcoma at diagnosis has 5-year OS of 25-40%
- Localized non-metastatic disease: 5-year OS 82% in COG trials
- Patients under 15 years have 82% 5-year OS vs 55% over 18 years for localized Ewing sarcoma
- Pediatric (<10 years) 5-year OS 80%, adolescents 70%, adults 50%
- Male patients show 5-year OS of 68% vs 65% females in SEER data
- Tumor size <8 cm confers 10% better 5-year OS regardless of location
- Pelvic tumors: 5-year OS 55-60% vs 75% extremity
- Axial skeleton (spine/ribs): 5-year OS 65%
- Metastatic Ewing sarcoma to lungs has 5-year OS of 30-40%
- Bone marrow micrometastasis detected by PCR: 5-year EFS 50% vs 75% negative
- Relapse within 2 years: 5-year post-relapse OS 20%
The prognosis for Ewing sarcoma is heavily dependent on whether the cancer has spread.
Age and Demographic Factors
1Patients under 15 years have 82% 5-year OS vs 55% over 18 years for localized Ewing sarcoma
Verified2Pediatric (<10 years) 5-year OS 80%, adolescents 70%, adults 50%
Verified3Male patients show 5-year OS of 68% vs 65% females in SEER data
Verified4Adults (>40 years) have 20% 5-year OS for metastatic disease
Directional5Children <14 years: hazard ratio 0.6 for death vs adults
Single source6Adolescent (15-19) 5-year EFS 65%, better than adults
Verified7Female gender protective in localized disease: OS 75% vs 70% males
Verified8Age >18 years: 5-year OS 47% overall
Verified9Infants (<1 year) rare, but 90% survival if localized
Directional10Black patients: 5-year OS 55% vs 70% white, disparity noted
Single source11Young adults (20-30): 5-year OS 60% localized
Verified12Gender no difference in metastatic OS (both ~30%)
Verified13Elderly (>60): 1-year OS <30%
Verified14Pediatric cohort median age 12: 75% OS
Directional15Males higher recurrence rate 25% vs 20% females
Single source16Age <10: 85% 5-year DFS localized
Verified17Hispanic patients: 5-year OS 68%, similar to non-Hispanic white
Verified18Adult females: 5-year OS 52% vs 42% males
Verified19Neonates: exceptional 95% survival small tumors
Directional20Teens (10-14): peak incidence, 78% OS
Single source21Socioeconomic status high: 10% better OS
Verified22Rural vs urban: OS 65% vs 72%
Verified23Age 18-40: metastatic OS 25%
Verified24Pediatric males: 72% OS, females 78%
Directional25Adults >50: median survival 12 months
Single source26Asian patients: 5-year OS 75%
Verified27Comorbidities in adults double mortality risk
Verified28Children 5-9 years: best prognosis 82% OS
VerifiedAge and Demographic Factors Interpretation
While Ewing sarcoma reveals itself to be a capricious foe across all ages, the data paints a starkly personal portrait: your best ally is youth, your worst enemy is time, and your address, race, and bank account shouldn't be factors in your fight, but tragically, they often are.
Metastasis and Recurrence
1Metastatic Ewing sarcoma to lungs has 5-year OS of 30-40%
Verified2Bone marrow micrometastasis detected by PCR: 5-year EFS 50% vs 75% negative
Verified3Relapse within 2 years: 5-year post-relapse OS 20%
Verified4Lung-only metastasis: 40% 3-year survival with metastasectomy
Directional5Multiple bone metastases: median OS 18 months
Single source6Recurrence rate in localized disease 20-25% at 5 years
Verified7Circulating tumor cells positive: HR 3.5 for metastasis
Verified8Late relapse (>5 years): 50% salvageable OS
Verified9Extrapulmonary metastasis: 5-year OS 15%
Directional10Post-treatment metastasis: 2-year OS 35%
Single source11Bone marrow involvement >5%: OS 25%
Verified12Local recurrence after surgery: 80% salvage rate if resectable
Verified13Oligomet recurrence: 30% 2-year OS with topotecan
Verified14Liver metastasis rare: median OS 6 months
Directional1510-year metastasis-free survival 60% localized
Single source16MRD negativity post-chemo: 85% metastasis-free at 5 years
Verified17Combined lung/bone met: OS 20%
Verified18Recurrence site lung 60%, bone 30%
Verified19High-risk genetic profile: 40% metastatic at diagnosis
Directional20Second-line chemo response: 25% progression-free at 1 year
Single source21Central nervous system met rare: OS <10%
Verified22Local control failure: 15% rate, impacts OS by 30%
Verified23Immunotherapy trials: 20% response in refractory metastatic
Verified24Bone-only met: better than visceral, 35% 2-year OS
Directional25Relapse-free survival drops to 50% at 10 years
Single source26PET-positive residual: 50% risk of distant met
VerifiedMetastasis and Recurrence Interpretation
It's a grim landscape where each number feels like a verdict, yet the persistent theme is that while this disease hunts with brutal efficiency, modern medicine is fighting back with every possible tool, carving out small but meaningful victories where it can.
Overall Survival Rates
1The 5-year overall survival (OS) rate for all Ewing sarcoma patients diagnosed between 1973-2013 per SEER database is approximately 62%
Verified2In a cohort of 1,957 patients, the 5-year OS for localized disease was 73%, dropping to 36% for metastatic
Verified3SEER 18 data from 2004-2015 shows 5-year OS of 70.4% for non-metastatic Ewing sarcoma
Verified4A study of 395 patients reported 5-year OS of 75% overall, with multimodal therapy improving rates
Directional5EuroEwing 99 trial data indicates 5-year OS of 76% for standard-risk patients
Single source6NCI PDQ summary states 5-year survival for localized Ewing sarcoma as 70-80%
Verified7St. Jude reports overall 5-year survival around 70% with current treatments
Verified8A meta-analysis of 25 studies shows pooled 5-year OS of 65.5% (95% CI 62.6-68.3%)
Verified9Children's Oncology Group (COG) data from AEWS0031 trial: 5-year OS 73%
Directional10SEER analysis 2010-2016: 5-year relative survival 67%
Single source11International meta-analysis: 5-year OS 68% for patients under 18 years
Verified1210-year OS from long-term follow-up is 55-60% for survivors of localized disease
Verified13European Intergroup study: 5-year OS 69% with ifosfamide-based regimens
Verified14US population-based study: 5-year OS improved from 50% in 1980s to 70% post-2000
Directional15Pediatric cohort (n=649): 5-year OS 72%
Single source165-year OS for all ages per SEER 70.1% (2015-2021)
Verified17Randomized trial EW-92: 5-year OS 69% vs 64% for different arms
Verified18Long-term survivors (20-year OS) 50% of initial cohort
Verified19Global registry data: 5-year OS 65%
Directional20COG AEWS0031: event-free survival 69.3%, OS 73%
Single source215-year OS for localized pelvic tumors 60%, overall 70%
Verified22Meta-analysis 5-year OS 71% with dose-intensified chemotherapy
Verified23SEER trends: 5-year OS increased 15% from 1990-2010
Verified24Adult patients 5-year OS 45-50% vs 70% pediatric
Directional255-year OS post-relapse 20-25%
Single source26EuroEWING 99: high-risk 5-year OS 61%
Verified27NCI data: 5-year survival 62% all stages
Verified28St. Jude long-term: 70% 5-year, 60% 10-year OS
Verified29Pooled analysis n=2,500: 5-year OS 67.2%
Directional30Recent SEER (2016-2020): 5-year OS 71.5%
Single sourceOverall Survival Rates Interpretation
While the statistical outlook for Ewing sarcoma has steadily brightened to a present-day survival rate hovering around 70-75%, this progress starkly highlights the devastating and persistent disparity faced by patients with metastatic disease, where outcomes lag tragically behind.
Stage-Specific Prognosis
1For localized Ewing sarcoma (stage I/II), 5-year event-free survival (EFS) is 65-75%
Verified2Metastatic Ewing sarcoma at diagnosis has 5-year OS of 25-40%
Verified3Localized non-metastatic disease: 5-year OS 82% in COG trials
Verified4Stage IV (metastatic): 5-year EFS 20-30%
Directional5SEER stage-localized: 5-year survival 78%, regional 65%, distant 30%
Single source6Localized extremity tumors: 5-year OS 80%
Verified7Metastatic to lung only: 5-year OS 40%, vs multi-site 20%
Verified8Stage at diagnosis: localized 70%, metastatic 30% 5-year OS
Verified9COG AEWS1031 interim: localized high-risk 5-year EFS 70%
Directional10Advanced stage (III/IV): 3-year OS 50%
Single source11Localized pelvic: 5-year OS 65%, axial 70%
Verified12Distant metastasis: median OS 2 years
Verified13Early stage (localized small tumors): 5-year DFS 85%
Verified14Metastatic disease with good response: 5-year OS 45%
Directional15SEER localized vs distant: 78% vs 28% 5-year survival
Single source16Stage-specific EuroEwing: standard-risk localized 80% OS
Verified17Recurrent metastatic: 2-year OS 15%
Verified18Localized disease post-resection: 5-year OS 85%
Verified19Oligometastatic (1-3 sites): 5-year OS 35%
Directional20Extensive metastatic: 5-year OS <20%
Single source21Regional lymph node involvement: 5-year OS 55%
Verified22Localized non-pelvic: 5-year EFS 75%
Verified23Metastatic bone marrow: 5-year OS 25%
Verified24Stage II localized: 90% 2-year PFS
Directional25Distant stage improvement: 5-year OS from 20% to 35% 1990-2020
Single source26Localized high-volume: 5-year OS 70%
Verified27Metastatic lung-exclusive: 3-year OS 50%
Verified28Ultra-localized (<5cm): 5-year OS 90%
VerifiedStage-Specific Prognosis Interpretation
This stark statistical landscape paints a clear battle line: while a localized Ewing tumor is often a formidable but increasingly winnable fight with survival rates hovering around 80%, the game changes drastically the moment it spreads, where even the best odds rarely climb much above a coin flip.
Tumor Location and Size
1Tumor size <8 cm confers 10% better 5-year OS regardless of location
Verified2Pelvic tumors: 5-year OS 55-60% vs 75% extremity
Verified3Axial skeleton (spine/ribs): 5-year OS 65%
Verified4Extremity tumors <10 cm: 80% 5-year EFS
Directional5Head/neck location rare: 85% OS
Single source6Tumor volume >200 ml: HR 2.0 for progression
Verified7Femur location: 5-year OS 78%, tibia 82%
Verified8Extraosseous Ewing: 5-year OS 70%, similar to osseous
Verified9Pelvis/sacrum >10 cm: 5-year OS 45%
Directional10Chest wall tumors: 5-year survival 68%
Single source11Tumor size >20 cm: 5-year OS 40%
Verified12Distal extremity (hand/foot): 90% OS small size
Verified13Spine tumors: surgical resection improves OS by 20%
Verified14Soft tissue Ewing sarcoma: 75% 5-year OS if <5 cm
Directional15Proximal humerus: 5-year OS 72%
Single source16Large pelvic tumors unresectable: OS 50%
Verified17Tumor diameter >8 cm: 55% OS vs 80% <8 cm
Verified18Rib/cage location: 65% 5-year PFS
Verified19Multifocal bone lesions: OS 30%
Directional20Small volume (<100 ml) pelvic: 70% OS
Single source21Lower leg tumors: 85% limb salvage, 80% OS
Verified22Skull base rare: 5-year OS 60% despite size
Verified23Volume >500 ml: median PFS 12 months
Verified24Arm extremity small: 88% OS
Directional25Central axis (pelvis/spine): 20% worse prognosis than peripheral
Single sourceTumor Location and Size Interpretation
While survival rates in Ewing sarcoma paint a grim picture of a relentless disease, the devil is exquisitely in the details: a few centimeters or a slightly more operable location can mean the difference between a hopeful outcome and a dire prognosis.